Join the club for FREE to access the whole archive and other member benefits.

Marina Cavazzana

Co-Founder and Acting CMO at Smart Immune, hematopoietic stem cell-based biotherapies

MARINA CAVAZZANA is a pediatrician, Professor of Hematology since 2000, Director of the Department of Biotherapy at Necker Hospital, Paris Descartes University. She is the Director of the Inserm / Assistance Publique – Hôpitaux de Paris GHU Ouest Biotherapy Clinical Investigation Center and leads the research “Human lymphohematopoiesis” Laboratory at Imagine Institute.

Her main research and clinical interests are the development of the hematopoietic immune system, and cell and gene therapy for inherited and acquired disease of the hematopoietic system. Her group studies the means to improve the clinical results of hematopoietic stem cell transplantation, crossing HLA-barriers, and the differentiation of mouse and human stem cells towards lymphocyte lineages. She has initiated several clinical trials based on the use of ex vivo gene modified hematopoietic stem cells to treat patients with inherited disorders, the preliminary clinical results of which are encouraging. She is the author or co-author of one patent and of more than 270 publications in peer-reviewed journals and was awarded 2 ERC (2011 and 2016).

 marina-cavazzana-954753a0

See also: Company Smart Immune - Biotechnology company focused on developing the next generation of hematopoietic stem cell-based biotherapies

Details last updated 20-Jun-2020

Marina Cavazzana News

CRISPR gene editing to cure beta thalassaemia and sickle cell disease

CRISPR gene editing to cure beta thalassaemia and sickle cell disease

New Scientist - 12-Jun-2020

Didn't change the inherited faulty gene, but gene to switch on fetal haemoglobin production

Gene therapy cures boy of sickle cell disease

Gene therapy cures boy of sickle cell disease

New Scientist - 01-Mar-2017

People with sickle cell disease make abnormal versions of haemoglobin – distorting red blood cell...